Theramex news

This website is intended for an international audience. To view your own country’s website if available, please select your country from the list provided.

View your own country’s website

Australia
België
Belgique
Brazil
España
France
Italia
Netherlands
Polski
Portugal
UK

26 February 2025

Accelerating Action for Women: Driving Equality in Healthcare, the Workplace, and Beyond

20 December 2024

Theramex Announces European Commission Approval for Yselty®▼ (linzagolix) for Symptomatic Treatment of Endometriosis in Women with a History of Previous Medical or Surgical Treatment for their Endometriosis

17 December 2024

Theramex’s Sustainability Report 2023

13 September 2024

Theramex announces the first sale of Yselty®▼ (linzagolix) in Germany

11 December 2023

Theramex Announces Completion of its Acquisition of the Femoston® and Duphaston® Products in Europe (ex-UK) from Viatris.

1 December 2023

Theramex Office Opening and Panel Discussion

A dedicated women's health company

Understanding contraceptive options to meet your needs

Supporting you through the menopause

Helping you thrive through osteoporosis

Helping you through the challenges of fertility

Our diverse portfolio helps us deliver on our commitment to Women's Health

Get in touch

Careers

Theramex news

Accelerating Action for Women: Driving Equality in Healthcare, the Workplace, and Beyond

Theramex Announces European Commission Approval for Yselty®▼ (linzagolix) for Symptomatic Treatment of Endometriosis in Women with a History of Previous Medical or Surgical Treatment for their Endometriosis

Theramex’s Sustainability Report 2023

Theramex announces the first sale of Yselty®▼ (linzagolix) in Germany

Theramex Announces Completion of its Acquisition of the Femoston® and Duphaston® Products in Europe (ex-UK) from Viatris.

Theramex Office Opening and Panel Discussion

Read more about Theramex

Theramex news

Accelerating Action for Women: Driving Equality in Healthcare, the Workplace, and Beyond

Theramex Announces European Commission Approval for Yselty®▼ (linzagolix) for Symptomatic Treatment of Endometriosis in Women with a History of Previous Medical or Surgical Treatment for their Endometriosis

Theramex’s Sustainability Report 2023

Theramex announces the first sale of Yselty®▼ (linzagolix) in Germany

Theramex Announces Completion of its Acquisition of the Femoston® and Duphaston® Products in Europe (ex-UK) from Viatris.

Theramex Office Opening and Panel Discussion

Read more about Theramex

You're about to leave our website